With commercial insurance: Genentech Oncology Co-pay Assistance Program — as little as $0, up to $25,000 per calendar year. With Medicare: the Rituxan card can’t be used. 6 foundation funds are open today (as of October 12, 2026). See them by diagnosis below.
See what this patient owes after assistance →
18 assistance programs for Rituxan patients · 8 open today
Manufacturer savings, charitable foundations, and patient assistance programs.
Select the patient's insurance and diagnosis to see which programs may apply.
Current status · Award amounts · Eligibility · Direct application links October 12, 2026
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Checked September 28, 2026 · Source ↗
Rituxan’s card can’t be used with Medicare. These funds may help. They open and close with donations, so call before telling a Rituxan patient no.
Checked September 28, 2026 · Source 1 ↗ · Source 2 ↗
Rituxan · Rheumatoid arthritis · Commercial insurance
Eligible patients may pay $0
Example · Rituxan · 1000 mg · 100 units · commercial plan · deductible met · 20% coinsurance · allowed amounts at the Medicare reference rate
| Without assistance | With Genentech Oncology Co-pay Assistance Program | |
|---|---|---|
| Drug responsibility | $1,441.88 | $0.00 |
| Administration (96413 + 96415) | $43.68 | $43.68 |
| Patient owes | $1,485.56 | $43.68 |
Estimated patient savings: $1,441.88
CareCost calculates the drug and administration lines using the patient’s payer rate and benefits; this example uses the Medicare rate as a reference.
Also available if this patient’s coverage falls short
Free Genentech Patient Foundation (Free Drug) for eligible patients
Change the diagnosis to see only the programs that apply to your patient.
Rituxan shares its class with Truxima (Q5115, Teva / Celltrion), Ruxience (Q5119, Pfizer), Riabni (Q5123, Amgen), Rituxan Hycela (J9311, Genentech), billed under their own codes with their own manufacturer programs. The programs above apply to Rituxan only. If the payer requires Truxima, Ruxience, Riabni or Rituxan Hycela instead of Rituxan, use that maker’s program below.
Each Truxima, Ruxience, Riabni or Rituxan Hycela card shows the date we last checked that program. Copay cards also say whether they pay the infusion or injection fee.
TRUXIMA Cost Support Program
Pfizer Oncology Together Co-Pay Savings Program for Injectables (Ruxience)
Amgen SupportPlus Co-Pay Program (Riabni)
Genentech Oncology Co-pay Assistance Program
Genentech Patient Foundation (Free Drug)
| Task | ✓ |
|---|---|
| Find programs for the diagnosis | ✓ |
| See whether each program is open | ✓ |
| See maximum award | ✓ |
| Review key eligibility requirements | ✓ |
| Open the official application | ✓ |
| Calculate cost before assistance | ✓ |
| Apply the program benefit | ✓ |
| Calculate what the patient still owes | ✓ |
Commercial insurance — Eligible commercially insured patients may qualify for Genentech's Co-pay Assistance Program, which pays part of both the drug and administration cost per infusion. View current program ↑
Medicare — Manufacturer copay savings cannot be used when government insurance is paying for Rituxan; the federal Anti-Kickback Statute is why, per HHS OIG guidance on copayment coupons. Diagnosis-specific charitable foundations may still help: HealthWell's ANCA-associated vasculitis and granulomatosis with polyangiitis fund fits granulomatosis with polyangiitis and microscopic polyangiitis; no foundation fund on file covers rheumatoid arthritis (check each fund's current status on the funds list). View current Medicare funds ↑
Why fund status matters — Foundation funds can change between: OPEN Accepting applications now · WAITLIST Not enrolling immediately · CLOSED Not accepting new applications. Every CareCost program card shows the status and the date it was verified.
Why diagnosis matters — Foundation assistance is generally organized around the patient's diagnosis rather than the drug alone. A rheumatoid arthritis patient and a granulomatosis with polyangiitis patient on the same Rituxan infusion can end up with completely different assistance options.
Yes, for commercially insured patients only. Genentech's Co-pay Assistance Program brings a Rituxan (J9312) infusion to $5 for the drug and $5 for the administration, under one annual maximum; the current award amount and status are on the program card above. Apply on Genentech Oncology Co-pay Assistance Program Program ↗ Calculate cost with the program →
No. Patients using Medicare or other government-funded insurance to pay for Rituxan are not eligible for the manufacturer's copay savings program. Independent charitable funds may still be available: HealthWell's ANCA-associated vasculitis and granulomatosis with polyangiitis fund fits granulomatosis with polyangiitis and microscopic polyangiitis; no foundation fund on file covers rheumatoid arthritis (check each fund's current status on the funds list). Check current Medicare funds ↑
Yes. HealthWell's ANCA-associated vasculitis fund is open to the M31.30 and M31.7 diagnoses that carry a J9312 claim, so it covers granulomatosis with polyangiitis and microscopic polyangiitis; its current status and award amount are on the program card above. Check today's status ↑
Data current: programs verified Oct 12, 2026
Genentech Oncology Co-pay Assistance Program Program · Genentech Patient Foundation · HealthWell Foundation · TotalAssist (Patient Advocate Foundation) · CancerCare · Good Days · Blood Cancer United · PAN Foundation · The Assistance Fund · TRUXIMA Cost Support Program (Truxima) · Pfizer Oncology Together Co-Pay Savings Program for Injectables (Ruxience) · Amgen SupportPlus Co-Pay Program (Riabni). Every program links directly to its official source or application page.
Last program check: .
Reviewed September 22, 2026 by Erin Rose, CareCost Estimate founder. Methodology →
CareCost